Literature DB >> 12898509

Pro-apoptotic activity of transiently expressed BCL-2 occurs independent of BAX and BAK.

T Subramanian1, G Chinnadurai.   

Abstract

BCL-2 suppresses apoptosis induced by a wide variety of stimuli in multiple cell types. Most of the in vitro studies that have examined the activity of BCL-2 have employed stable cell lines that ectopically express BCL-2. We have reported that BCL-2 is expressed at high levels in the absence of the 5'- and 3'-UTRs of the Bcl-2 gene and transient high level of expression results in potent cell death (Uhlmann et al., [1998]: JBC 278:17926-17932). Expression of BCL-2 under the transcriptional control of the cognate 5'- and 3'-UTRs express lower levels of BCL-2 and does not cause cell death. Our present results suggest that in contrast to BCL-2, transient expression of BCL-xL does not induce cell death and coexpression of BCL-xL with the pro-apoptotic BCL-2 does not suppress cell death. The pro-apoptotic activity of BCL-2 appears to involve activation of the cytochrome c/caspase 9/caspase 3 pathway. Elevated levels of BCL-2 expression results in N-terminal cleavage of BCL-2 at a novel site different from a previously identified caspase cleavage site at Asp 34 by a non-caspase protease. Transient expression of a BCL-2 mutant lacking aa 51-85 within the loop region induces efficient cell death and N-terminal cleavage of BCL-2 while a different deletion mutant lacking aa 30-91 induces reduced levels of cell death in the absence of BCL-2 cleavage suggesting that N-terminal processing of BCL-2 may be an amplification event in BCL-2-mediated cell death. Overexpression of BCL-2 in a Bax-null human colon cancer cell line (HCT116Bax-/-) induces efficient cell death. The pro-apoptotic activity of BCL-2 is also observed in a Bax-null cells in which BAK expression is inhibited by stable RNAi expression. Our results suggest that BCL-2 contains an intrinsic pro-apoptotic activity and can induce apoptosis independent of BAX and BAK under specific conditions. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898509     DOI: 10.1002/jcb.10573

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma.

Authors:  Frederic Luciano; Maryla Krajewska; Paulina Ortiz-Rubio; Stan Krajewski; Dayong Zhai; Benjamin Faustin; Jean-Marie Bruey; Beatrice Bailly-Maitre; Alan Lichtenstein; Siva Kumar Kolluri; Arnold C Satterthwait; Xiao-Kun Zhang; John C Reed
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

2.  Genetic identification of adenovirus type 5 genes that influence viral spread.

Authors:  T Subramanian; S Vijayalingam; G Chinnadurai
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  In vivo and in vitro estrogenic and progestagenic actions of Tibolone.

Authors:  Anil Sadarangani; Ana María Salgado; Sumie Kato; Mauricio Pinto; Andrés Carvajal; Carolina Monso; Gareth I Owen; Pilar Vigil
Journal:  Biol Res       Date:  2005       Impact factor: 5.612

4.  N-methyl-D-aspartate and TrkB receptors protect neurons against glutamate excitotoxicity through an extracellular signal-regulated kinase pathway.

Authors:  Daming Zhu; Xuan Wu; Kenneth I Strauss; Robert H Lipsky; Zehra Qureshi; Artin Terhakopian; Antonello Novelli; Krishna Banaudha; Ann M Marini
Journal:  J Neurosci Res       Date:  2005-04-01       Impact factor: 4.164

5.  Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death.

Authors:  S Maddika; G H Bay; T J Kroczak; S R Ande; S Maddika; E Wiechec; S B Gibson; M Los
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

6.  Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode.

Authors:  B Gillissen; A Richter; A Richter; T Overkamp; F Essmann; P G Hemmati; R Preissner; C Belka; P T Daniel
Journal:  Cell Death Dis       Date:  2013-05-23       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.